A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma

Publisher： Karger

E-ISSN： 1423-0232|80|1-2|50-56

ISSN： 0030-2414

Source： Oncology, Vol.80, Iss.1-2, 2011-05, pp. : 50-56

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma

By  

CANCER, Vol. 121, Iss. 8, 2015-04 ,pp. : 1223-1230

John Wiley & Sons Inc

Access to resources Recommend Favorite

Soft Tissue Sarcoma: An Update on Systemic Treatment Options for Patients with Advanced Disease

By  

Oncology Research and Treatment, Vol. 37, Iss. 6, 2014-04 ,pp. : 355-362

Karger

Access to resources Recommend Favorite

A phase II study to determine the efficacy and safety of oral treosulfan in patients with advanced pre‐treated Ewing sarcoma ISRCTN11631773

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 1, 2015-01 ,pp. : 158-159

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I Study of Weekly Docetaxel and Liposomal Doxorubicin in Patients with Advanced Solid Tumors

By  

Oncology, Vol. 69, Iss. 3, 2005-10 ,pp. : 202-207

Karger

Access to resources Recommend Favorite

A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma

By  

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3481-3490

John Wiley & Sons Inc

Access to resources Recommend Favorite